THE
NATIONAL LAW REVIEW

Driving the Deal: FDA Considerations [PODCAST]

McDermott Will & Emery

Article By
Vernessa T. Pollard
McDermott Will & Emery
Health Care Law Reform

- Administrative & Regulatory
- Health Law & Managed Care

- All Federal

Wednesday, June 26, 2019

The Food and Drug Administration (FDA) has recently publicly recognized that collaboration is a key priority as they work to safely bring cutting-edge devices and treatments to market. On this episode of the Collaborative Transformation podcast series, Life Sciences lawyers Vernessa Pollard, Veleka Peeples-Dyer and Khelin Aiken discuss trends and opportunities in the market as they relate to deals involving FDA-regulated products, including:

- Leadership transitions at the FDA, the push toward modernization of products and product development, and what that means for the life sciences and digital health dealmaking environment.
- Benefits of the FDA's new approach to transparency and collaboration with the life sciences industry for both companies and investors.
- Industry collaboration opportunities emerging from FDA's rare disease product development priorities, product-specific guidance and fast-tracked designations.
- The increased involvement of contract manufacturing organizations and contract research organizations in life sciences and what that means for collaborations and dealmaking.
- The role of FDA programs like the Digital Health Software Precertification

Program and rules like the 21st Century Cures Act in driving innovation in life sciences.